ClinicalTrials.gg
CompletedNCT03677648Updated Mar 15, 2023

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

A Phase 2 interventional study of SHR0302 and Placebos in Crohn's Disease, sponsored by Reistone Biopharma Company Limited. Completed at 82 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 192 studies in Crohn Disease with a site in China — 75 open to participants now, 88 under way, 22 of them phase 3. Crohn Disease · China.

Enrollment
63rd of 129
112 · median 110
Started
2019
with 7 others
Phase 2
16 of 192
6 open now
Registered
50th of 192
by date

Among the 192 studies in Crohn Disease with a site in China, this one is the 63rd largest by enrollment of the 129 interventional ones that give a count, is one of 8 that started in 2019, is one of 16 in phase 2, and was the 50th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

75 of the 192 studies in Crohn Disease with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Crohn Disease with a site in China, or all of them as a file.
02

Study summary

The proposed study is a randomized, double-blind, placebo-controlled, multi-center Phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active Crohn's Disease. The study aims to evaluate the optimal dose of SHR0302 and time needed in inducing clinical remission in active CD. This is an 12+12 weeks study, in which participants who complete the first 12 weeks treatment phase, will have the option to enter a blinded active arms 12-week extension phase. Early withdrawn subjects during the first treatment phase cannot enter the extension phase. The total duration of the study participation, including extension and follow-up, will be approximately 26 weeks.

With the wealth of scientific evidence on JAK/STAT involvement in IBD, the data from similar class of new drugs and the current data on SHR0302 (JAK1 inhibitor), support the rationale to proceed with phase II studies to evaluate the efficacy and safety of SHR0302 in patients with moderate to severe active CD.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subject at ≥18 and ≤ 75 years of age at randomization.
  • Subjects with a documented three-month history of diagnosed ileal, colonic, or ileocolonic Crohn's Disease at the time of randomization.
  • Currently having Crohn's Disease with Crohn's Disease Activity Index (CDAI) score ≥ 220 to ≤450.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, or clinical findings suggestive of Ulcerative Colitis.
  • Subject with CD with stoma, gastric or ileoanal pouch, proto-colectomy or total colectomy, symptomatic stenosis or stricture, history of bowel perforation, suspected abscess; actively draining fistula.
  • Treatment naïve subjects diagnosed with Crohn's disease, (without previous exposure to treatment).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Active comparator
    SHR0302 dose A

    Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.

    Drug: SHR0302

  • Experimental
    SHR0302 dose B

    Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.

    Drug: SHR0302

  • Experimental
    SHR0302 dose C

    Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.

    Drug: SHR0302

  • Placebo comparator
    Placebo

    Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.

    Drug: SHR0302 · Drug: Placebos

Interventions

  • The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

  • DrugPlacebos

    Placebos

06

What researchers measure

Primary outcomes

  1. The percentage of subjects achieving clinical remission at week 12.

    The percentage of subjects achieving clinical remission at week 12, defined as Crohn's Disease Activity Index (CDAI) score \< 150.

    Time frame: week12

Secondary outcomes

  1. The percentage of subjects achieving clinical remission defined as mean daily stool frequency (SF) ≤2.5, and abdominal pain (AP) ≤ 1 using the Patient Reported Outcome from CDAI at week 1, 4, 8, 12, 13, 16, and 24.

    The percentage of subjects achieving clinical remission defined as mean daily stool frequency (SF) ≤2.5, and abdominal pain (AP) ≤ 1 using the Patient Reported Outcome from CDAI at week 1, 4, 8, 12, 13, 16, and 24.

    Time frame: week 1, 4, 8, 12, 13, 16, and 24

  2. The percentage of subjects achieving clinical remission defined as PRO2 < 8 at week 1, 4, 8, 12, 13, 16, and 24.

    The percentage of subjects achieving clinical remission defined as PRO2 \< 8 at week 1, 4, 8, 12, 13, 16, and 24.

    Time frame: week 1, 4, 8, 12, 13, 16, and 24

  3. The percentage of subjects achieving clinical response defined as a CDAI decrease from baseline of ≥ 100 points at week 1, 4, 8, 12, 13, 16, and 24.

    The percentage of subjects achieving clinical response defined as a CDAI decrease from baseline of ≥ 100 points at week 1, 4, 8, 12, 13, 16, and 24.

    Time frame: week 1, 4, 8, 12, 13, 16, and 24

07

Study locations

82 sites
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33756, United States
  • Wellness Clinical Research, LLLC-Central Florida
    Lake Wales, Florida 33853, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Tampa, Florida 33626, United States
  • NECCR Primacare Research, LLC
    Fall River, Massachusetts 02721, United States
  • Wilmington Health
    Wilmington, North Carolina 28401, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Yijishan Hospital of Wannan Medical College
    Yingshan, Anhul 241001, China
  • Peking University Third Hospital
    Beijing, Beijing 10083, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Nanchang University
    Guangzhou, Guangzhou 510515, China
  • The Sixth Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangzhou 510655, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Tongji Hospital Affiliated to Tongji Medicine College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Henan Provincial People's Hospital
    Pingxiang, Hunan 337005, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213002, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Yangzhou First People's Hospital
    Yangzhou, Jiangsu 225001, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The first Hospital of Jilin University
    Changchun, Jilin 130061, China
  • Ruijin Hospital, Shanghai Jiaotong University, School of Medicne
    Shanghai, Shanghai 200025, China
  • Shanghai Xinhua Hospital
    Shanghai, Shanghai 200092, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200120, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai 200433, China
  • Tianjin Union Medical Center
    Tianjin, Tianjin 300121, China
  • Sir Run Run Shaw Hospital, Affiliated with the Zhejiang University School of Medicine
    Hangzhou, Zheijiang 310020, China
  • Huzhou Central Hospital
    Huzhou, Zheijiang 313003, China
  • Nanfang Hospital of Southern Medical University
    Changchun, 130021, China
  • Xiangya Hospital Central South University
    Changsha, 410008, China
  • st China Hospital Sichuan University
    Chengdu, 610041, China
  • Fujian Provincial Hospital
    Fuzhou, 350001, China
  • Qilu Hospital of Shandong University
    Jinan, 250012, China
  • Jiangsu Province Hospital
    Nanjing, 210006, China
  • Nanjing First Hospital
    Nanjing, 210006, China
  • The Affiliated Hospital of Nanjing University School
    Nanjing, 210008, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200127, China
  • The University of Hong Kong-Shenzhen Hospital
    Shenzhen, 518053, China
  • Shanxi Provincial People's Hospital
    Taiyuan, 030001, China
  • Second hospital of Shanxi Medical university
    Taiyuan, 030012, China
  • Indywidualma Specjalistyczna Praktyka Lekarska Maciej Zymla
    Knurów, 44-190, Poland
  • Nzoz Allmedica Badania
    Nowy Targ, 34400, Poland
  • Provita Profamilia
    Piotrków Trybunalski, 97300, Poland
  • SOLUMED Centrum Medyczne
    Poznań, 60-529, Poland
  • KO-MED Central Kliniczne Plulawy
    Puławy, 24-100, Poland
  • Gabinet Lekarski Bartosz Korczowski
    Rzeszów, 35-302, Poland
  • Specjalistyczna Praktyka Lekarska dr med. Marek Horynski
    Sopot, 81-756, Poland
  • KO-MED Centra Kliniczne Staszow
    Staszów, 28-200, Poland
  • Centrum Zdrowia MDM
    Warszawa, 00-635, Poland
  • Centralny Szpital Kliniczny MSW
    Warszawa, 02507, Poland
  • Nzoz Vivamed
    Warszawa, 03-580, Poland
  • PlanetMed sp. z o.o.
    Wrocław, 53-333, Poland
  • Amicare Sp. z o.o. Sp.k
    Łódź, 90-644, Poland
  • SALVE Zakład Opieki Zdrowotnej Sp. zo.o.
    Łódź, 91-211, Poland
  • EZ-MED Centrum Medyczne
    Świdnica, 58-100, Poland
  • RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU
    Chernivtsi, 58002, Ukraine
  • I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital
    Dnipro, 49005, Ukraine
  • I.I.Mechnykov Dnipropetrovsk
    Dnipro, 49005, Ukraine
  • Ivano-Frankivsk Hospital
    Ivano-Frankivs'k, 76018, Ukraine
  • Ivano-Frankivsk Med. University
    Ivano-Frankivs'k, 76018, Ukraine
  • CHI Kharkiv City Clinical Hospital #13
    Kharkiv, 61124, Ukraine
  • Public nonprofit enterprise
    Kharkiv, 61172, Ukraine
  • Kherson City Clinical Hospital
    Kherson, 7300, Ukraine
  • Khmelnyski Regional Hospital
    Khmelnytskyi, 29000, Ukraine
  • Tx-Dx Center Adonis Plus Ltd
    Kiev, 2002, Ukraine
  • Healthy and Happy
    Kyiv, 01033, Ukraine
  • Kyiv City Clinical Hospital
    Kyiv, 02091, Ukraine
  • Kyiv Clin Hospital on Railway St. 2
    Kyiv, 03049, Ukraine
  • Med. Cen.of Limited Liability
    Kyiv, 08711, Ukraine
  • Kyiv Regional Hospital #2
    Kyiv, Ukraine
  • Lviv Regional Clinical Hosp
    Lviv, 79010, Ukraine
  • Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU
    Lviv, 79059, Ukraine
  • Medical Center Pulse
    Vinnytsia, 21001, Ukraine
  • RCH Vinnytsia, Dept. Therapy
    Vinnytsia, 21005, Ukraine
  • Vinnytsia M I Pyrogov
    Vinnytsia, 21018, Ukraine
  • CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM
    Vinnytsia, 21029, Ukraine
  • Communal Institution Center of the Primary Medical- Sanitary Care#2
    Vinnytsia, 21050, Ukraine
  • Center of primary health care
    Vinnytsia, Ukraine
  • City Clinical Hospital
    Zaporizhzhya, 69035, Ukraine
  • O.F. Herbachevskiyi Zhytomyr Regional Clinical Hospital
    Zhytomyr, 10002, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Sep 2021, 28 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 28 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 19, 2018
StartActual
May 14, 2019
Primary completionActual
Sep 16, 2021
CompletionActual
Dec 9, 2021
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03677648
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
May 14, 2019
Primary completion
Sep 16, 2021
Completion
Dec 9, 2021
Last update
Mar 15, 2023

Study contacts

Xiang Chen
study director · Reistone Biopharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion